기본 통계
| CIK | 1708527 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aziyo Biologics Inc - Class A
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 14, 2026 |
Exhibit 99.1 Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market ● NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations ● Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale ● Chief Commercial Officer Pete Ligot |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2026 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Elutia Inc. (Exact |
|
| April 22, 2026 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Con |
|
| April 22, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 25, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 ELUTIA INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A Common Stock, $0.001 par value Other 1,540,000 $ 1.08 $ 1,663,200.00 0.0001381 $ 229.69 2 Equity Class A Common S |
|
| March 25, 2026 |
As filed with the Securities and Exchange Commission on March 25, 2026 As filed with the Securities and Exchange Commission on March 25, 2026 Registration No. |
|
| March 13, 2026 |
Exhibit 21.1 SUBSIDIARIES OF ELUTIA INC. Legal Name of Subsidiary Jurisdiction of Organization Elutia Med LLC Delaware |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2026 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 11, 2026 |
Exhibit 99.1 Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process – Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m. PT – GAITHERSBURG, Md., |
|
| March 9, 2026 |
ELUTIA INC. 2026 INDUCEMENT AWARD PLAN ARTICLE 1. ELUTIA INC. 2026 INDUCEMENT AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Elutia Inc. 2026 Inducement Award Plan (as it may be amended or restated from time to time, the “Plan”) is to enhance the ability of Elutia Inc. (the “Company”) and its Subsidiaries to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with e |
|
| March 9, 2026 |
ELUTIA INC. 2026 INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT ELUTIA INC. 2026 INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Elutia Inc., a Delaware corporation (the “Company”), pursuant to its 2026 Inducement Award Plan, (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in th |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2026 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 4, 2026 |
Elutia Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Elutia Regains Compliance with Nasdaq Listing Requirements GAITHERSBURG, Md., March 4, 2026 — Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the mini |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2026 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2026 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 12, 2026 |
Exhibit 99.1 Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., January 12, 2026 - Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomat |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 12, 2025 |
Exhibit 10.42 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made between Elutia Inc. (the “Company”) and Guido Neels (the “Consultant”) (collectively, the “Parties”). WHEREAS, the Company desires to obtain the advice and counsel of the Consultant regarding the Company’s business and financial matters/matters within the Consultant’s experience and expertise; WHEREAS, the Compa |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 6, 2025 |
Exhibit 99.1 Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 (October 7, 2025) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Com |
|
| October 14, 2025 |
Exhibit 99.1 Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., October 10, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the |
|
| October 7, 2025 |
Exhibit 99.1 Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., October 1, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer |
|
| October 7, 2025 |
CONSENT, RELEASE AND AMENDMENT NO. 3 TO ROYALTY AGREEMENT Exhibit 10.2 CONSENT, RELEASE AND AMENDMENT NO. 3 TO ROYALTY AGREEMENT This Consent, Release and Amendment No. 3 to Royalty Agreement (this “Amendment”) is dated as of October 1, 2025 (the “Effective Date”), by and between Elutia Med LLC, a Delaware limited liability company (formerly known as Aziyo Med, LLC) (the “Company”), and Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Li |
|
| October 7, 2025 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On October 1, 2025, Elutia Inc. (the “Company”) completed the previously announced sale of its Device Protection segment (the “Device Protection Business”) to Boston Scientific Corporation (“BSC”) and Cardiac Pacemakers Inc. ("CPI", and together with BSC, the “Buyers”). The sale was structured as an asset sale, which occ |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 (October 1, 2025) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Comm |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 (September 8, 2025) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) ( |
|
| September 9, 2025 |
Exhibit 10.1 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. ASSET PURCHASE AGREEMENT BY AND AMONG BOSTON SCIENTIFIC CORPORATION AND CARDIAC PACEMAKERS INC., AS BUYERS, AND ELUTIA I |
|
| September 9, 2025 |
Exhibit 99.1 Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million - Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - G |
|
| August 20, 2025 |
FIFTH AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 FIFTH AMENDMENT TO CREDIT AGREEMENT THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of August 14, 2025, is entered into by and among ELUTIA INC., a Delaware corporation (f/k/a Aziyo Biologics, Inc.) (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liabili |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 14, 2025 |
Exhibit 99.1 Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., August 14, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologie |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 13, 2025 |
Exhibit 10.38 FOURTH AMENDMENT TO CREDIT AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of May 7, 2025, is entered into by and among ELUTIA INC., a Delaware corporation (f/k/a Aziyo Biologics, Inc.) (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liabilit |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 13, 2025 |
Exhibit 10.37 SUBSCRIPTION AGREEMENT AND AMENDMENT NO. 2 TO ROYALTY AGREEMENT May 8, 2025 WHEREAS, Elutia Med LLC. (formerly known as Aziyo Med, LLC), a Delaware limited liability company (“Elutia Med”), and Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), are parties to that certain Royalty Agreement dated as of May 31, 2017, as amended by Amendment No. 1 thereto effective |
|
| May 8, 2025 |
Exhibit 99.1 Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 8, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today reported s |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 8, 2025 |
ELUTIA INC. 1,105,528 Shares of Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-285870 PROSPECTUS SUPPLEMENT (To Prospectus dated April 7, 2025) ELUTIA INC. 1,105,528 Shares of Class A Common Stock We are issuing 1,105,528 shares of our Class A common stock directly to Ligand Pharmaceuticals Incorporated, or Ligand, in satisfaction of certain royalty obligations owed by our wholly owned subsidiary, Elut |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2025 (April 30, 2025) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commissio |
|
| May 6, 2025 |
Exhibit 99.1 Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 1, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovasc |
|
| April 11, 2025 |
ELUTIA INC. Up to $50,000,000 Shares of Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-285870 PROSPECTUS ELUTIA INC. Up to $50,000,000 Shares of Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the sales agreement, with Cantor Fitzgerald & Co., or the Agent, relating to the sale of shares of our Class A common stock, par value $0.001 per share, offered by this prospe |
|
| April 7, 2025 |
Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 April 7, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Elutia Inc. Registration Statement on Form S-3 Request for Acceleration of Effectiveness File No. 333-285870 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C, Elutia Inc. (the “Compa |
|
| April 4, 2025 |
TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| April 4, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Elutia Inc. (Exact |
|
| March 25, 2025 |
March 25, 2025 Matthew Ferguson Chief Financial Officer Elutia, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Re: Elutia, Inc. Registration Statement on Form S-3 Filed March 18, 2025 File No. 333-285870 Dear Matthew Ferguson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acc |
|
| March 18, 2025 |
As filed with the Securities and Exchange Commission on March 18, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 18, 2025 Registration No. |
|
| March 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ELUTIA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Carry Fo |
|
| March 18, 2025 |
Sales Agreement between Elutia Inc. and Cantor Fitzgerald & Co. dated March 17, 2025 Exhibit 1.2 ELUTIA INC. Shares of Class A Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement March 17, 2025 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Elutia Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issu |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 |
|
| March 11, 2025 |
Insider Trading Compliance Policy Exhibit 19 ELUTIA Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: ● Section I provides an overview; ● Section II sets forth the policies of the Company prohibiting insider trading; ● Section III explains insider trading; ● Section IV consists of procedures that have been put in place by the Company to prevent insider trading |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 6, 2025 |
Exhibit 99.1 Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out - Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization - SILVER SPRING, Md., March 6, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting bi |
|
| February 4, 2025 |
2025 Form of Prefunded Warrant Exhibit 4.1 form of PRE-FUNDED CLASS A COMMON STOCK PURCHASE WARRANT ELUTIA INC. Warrant Shares: Issue Date: February 4, 2025 Warrant No. THIS PRE-FUNDED CLASS A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 4, 2025 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT February 3, 2025 C. Randal Mills, Ph.D. President & Chief Executive Officer Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Dear Dr. Mills: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) and Elutia Inc., a company inco |
|
| February 4, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 3, 2025, between Elutia Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| February 4, 2025 |
Elutia Announces $15.0 Million Registered Direct Offering Exhibit 99.1 Elutia Announces $15.0 Million Registered Direct Offering SILVER SPRING, Md., February 3, 2025 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company’s Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purc |
|
| February 3, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267197 PROSPECTUS SUPPLEMENT (to Prospectus dated September 8, 2022) ELUTIA INC. 5,520,000 Shares of Class A Common Stock 480,000 Prefunded Warrants to Purchase up to 480,000 Shares of Class A Common Stock (and the Shares of Class A Common Stock Underlying the Prefunded Warrants) We are offering 5,520,000 shares of |
|
| February 3, 2025 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2024 |
Exhibit 99.1 Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., November 14, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update |
|
| October 15, 2024 |
ELUT / Elutia Inc. / SILVERARC CAPITAL MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 tm2426101d3sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elutia Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) October 11, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 3, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of September 30, 2024, is entered into by and among ELUTIA INC., a Delaware corporation (f/k/a Aziyo Biologics, Inc.) (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liab |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2024 |
Elutia Announces Second Quarter 2024 Results Exhibit 99.1 Elutia Announces Second Quarter 2024 Results Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., August 7, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the second quarter ended June 30, 2024 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 18, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT June 16, 2024 C. Randal Mills, Ph.D. President & Chief Executive Officer Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Dear Dr. Mills: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) and Elutia Inc., a company incorpo |
|
| June 18, 2024 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2024, between Elutia Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in |
|
| June 18, 2024 |
2024 Form of Prefunded Warrant Exhibit 4.1 form of PRE-FUNDED CLASS A COMMON STOCK PURCHASE WARRANT ELUTIA INC. Warrant Shares: Issue Date: June 18, 2024 Warrant No. THIS PRE-FUNDED CLASS A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| June 18, 2024 |
Elutia Announces $13.26 Million Registered Direct Offering Exhibit 99.1 Elutia Announces $13.26 Million Registered Direct Offering SILVER SPRING, Md., June 17, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purcha |
|
| June 17, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267197 PROSPECTUS SUPPLEMENT (to Prospectus dated September 8, 2022) ELUTIA INC. 3,175,000 Shares of Class A Common Stock 725,000 Prefunded Warrants to Purchase up to 725,000 Shares of Class A Common Stock (and the Shares of Class A Common Stock Underlying the Prefunded Warrants) We are offering 3,175,000 shares of |
|
| June 17, 2024 |
Exhibit 99.1 Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, includ |
|
| June 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 9, 2024 |
Exhibit 99.1 Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance SILVER SPRING, Md., May 9, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the first quarter ended March 31, 2024. Business |
|
| April 22, 2024 |
TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Co |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 1, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 1, 2024 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of March 27, 2024, is entered into by and among ELUTIA INC., a Delaware corporation (f/k/a Aziyo Biologics, Inc.) (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaw |
|
| March 11, 2024 |
Elutia Inc. Excess Incentive-based Compensation Recoupment Policy Exhibit 97 Excess Incentive-Based Compensation Recoupment Policy Effective October 2, 2023 This Excess Incentive-Based Compensation Recoupment Policy (this “Policy”) has been adopted by the Board of Directors of Elutia Inc. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 |
|
| March 7, 2024 |
Exhibit 99.1 Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024 SILVER SPRING, Md., March 7, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Business Highlights: · Achieved stron |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 20, 2024 |
ELUT / Elutia Inc. / Birchview Capital, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ELUTIA INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2024 |
AZYO / Aziyo Biologics Inc - Class A / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ELUTIA INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 05479K106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
ELUTIA INC. 18,577,644 Shares Class A Common Stock Offered by the Selling Securityholders Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-275666 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated December 4, 2023) ELUTIA INC. 18,577,644 Shares Class A Common Stock Offered by the Selling Securityholders This prospectus supplement updates and amends the prospectus dated December 4, 2023, which forms a part of our registration statement on Form S-3 (No. 333- 275666) file |
|
| February 7, 2024 |
AZYO / Aziyo Biologics Inc - Class A / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Elutia, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) January 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 2, 2024 |
Form of Stock Option Agreement under the Elutia Inc. Amended and Restated 2020 Incentive Award Plan. Exhibit 10.3 AZIYO BIOLOGICS, INC. AMENDED AND RESTATED 2020 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Elutia Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2020 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set f |
|
| February 2, 2024 |
Exhibit 10.2 AZIYO BIOLOGICS, INC. 2020 INCENTIVE AWARD PLAN AMENDMENT TO RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT THIS AMENDMENT TO THE RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT (the “Amendment”) by and between Elutia Inc., a Delaware corporation (the “Company”) and Charles Randal Mills (“Participant”) is effective as of the 3 |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 2, 2024 |
Exhibit 10.4 AZIYO BIOLOGICS, inc. AMENDED AND RESTATED 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit AWARD Grant Notice and restricted stock unit agreement Elutia Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2020 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted |
|
| February 2, 2024 |
Exhibit 10.1 AZIYO BIOLOGICS, INC. 2020 INCENTIVE AWARD PLAN AMENDMENT TO STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT THIS AMENDMENT TO THE STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT (the “Amendment”) by and between Elutia Inc., a Delaware corporation (the “Company”) and Charles Randal Mills (“Optionee”) is effective as of the 31st day of January, 2024 (the “Effective Date”). W |
|
| January 25, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Elutia Inc. (Exact Name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Equity Class A Common Stock, $0.0 |
|
| January 25, 2024 |
As filed with the Securities and Exchange Commission on January 25, 2024 As filed with the Securities and Exchange Commission on January 25, 2024 Registration No. |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 12, 2024 |
Amendment No. 1 to Royalty Agreement with Ligand Pharmaceuticals Incorporated Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO ROYALTY AGREEMENT This Amendment No. 1 to Royalty Agreement (this “Amendment”) is made effective as of January 10, 2024 (the “Amendment Effective Date”), by and between Elutia Med LLC, a Delaware limited liability company (formerly known as Aziyo Med, LLC) (the “Company”), and Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand” an |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 9, 2024 |
AZYO / Aziyo Biologics Inc - Class A / HighCape Capital, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elutia Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) W. Matthew Zuga 36 Church Lane Westport, CT 06880 (646) 793-3510 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Com |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2023 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 5, 2023 |
ELUTIA INC. 18,577,644 Shares Class A Common Stock Offered by the Selling Securityholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-275666 PROSPECTUS ELUTIA INC. 18,577,644 Shares Class A Common Stock Offered by the Selling Securityholders The selling securityholders may offer and sell up to 18,577,644 shares (the “Shares”) in the aggregate of Class A common stock identified above, of which (i) 6,852,811 shares are presently issued and outstanding, (ii) |
|
| December 4, 2023 |
AZYO / Aziyo Biologics Inc - Class A / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Elutia, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) September 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ |
|
| November 30, 2023 |
Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 November 30, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Elutia Inc. Registration Statement on Form S-3 Request for Acceleration of Effectiveness File No. 333- 275666 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C, Elutia Inc. (the “ |
|
| November 27, 2023 |
United States securities and exchange commission logo November 27, 2023 Matt Ferguson Chief Financial Officer ELUTIA INC. |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 20, 2023 |
As filed with the Securities and Exchange Commission on November 20, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 20, 2023 Registration No. |
|
| November 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Elutia Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Ca |
|
| November 20, 2023 |
Exhibit 99.1 Management’s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2022 Form 10-K. The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes included. This discussion contains forward-looking statements reflecting our current expectations, estimates, |
|
| November 15, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. TRANSITION TISSUE PROCESSING, SUPPLY AND DISTRIBUTION AGREEMENT THIS TRANSITION TISSUE PROCESSING, S |
|
| November 15, 2023 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On November 8, 2023, Elutia Inc. (the “Company”) completed the previously announced sale of its Orthobiologics segment (the “Orthobiologics Business”) to Berkeley Biologics, LLC (“Berkeley”). The sale was structured as an asset purchase, which occurred by divestiture of all the Orthobiologics Business assets and liabiliti |
|
| November 15, 2023 |
Amendment Letter, dated November 8, 2023, by and between Elutia Inc. and SWK Funding LLC Exhibit 10.1 November 8, 2023 Elutia Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Attn: Jeffrey D. Hamet RE: Amendment Letter Ladies and Gentlemen: Reference is made to (i) that certain Credit Agreement, dated as of August 10, 2022, by and among Elutia Inc., a Delaware corporation (f/k/a Aziyo Biologics, Inc.)(the “Borrower”), each of the undersigned financial institutions (indiv |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 (November 8, 2023) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2023 |
Exhibit 99.1 Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results - Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today provided a |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 9, 2023 |
Exhibit 99.1 Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million - Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 9, 2023 — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed the divestiture of its Orthobiologics business unit to Berk |
|
| November 7, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 (November 1, 2023) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Co |
|
| October 6, 2023 |
AZYO / Aziyo Biologics Inc - Class A / HighCape Capital, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elutia Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) W. Matthew Zuga 36 Church Lane Westport, CT 06880 (646) 793-3510 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Com |
|
| October 6, 2023 |
EX-1 2 tm2327986d1ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necess |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 (September 18, 2023) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) |
|
| September 21, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 21, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 18, 2023 by and among Elutia Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). Recitals A. The Company and each Investor is executing and deli |
|
| September 21, 2023 |
2023 Form of Prefunded Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 21, 2023 |
Exhibit 99.1 Elutia Announces Private Placement for Proceeds Up to $26 Million – Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sep. 19, 2023 — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it has entered into a securities purchase agreement for a private placement ( |
|
| September 21, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 21, 2023 by and among Elutia Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors identified on Exhibit A attached thereto (the “Purc |
|
| September 19, 2023 |
Exhibit 99.1 Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million – Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sep. 18, 2023 — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced the divestiture of the Company’s Orthobiologics bu |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (September 19, 2023 (September 17, 2023) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation |
|
| September 19, 2023 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. ASSET PURCHASE AGREEMENT by and among ELUTIA INC., as Seller, and Berkeley Biologics LLC, as Purchaser Dated as of September 17, 2023 TABLE OF CONTENTS Page Article I |
|
| September 7, 2023 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ELUTIA INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOM |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 (September 6, 2023) ELUTIA INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) ( |
|
| September 7, 2023 |
Exhibit 99.1 Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices – Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., September 6, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary dru |
|
| September 7, 2023 |
Certificate of Amendment to the Restated Certificate of Incorporation of Elutia Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF AZIYO BIOLOGICS, INC. Aziyo Biologics, Inc. (“Aziyo”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the corporation’s Restated Certificate |
|
| August 14, 2023 |
Exhibit 99.1 Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING |
|
| August 14, 2023 |
Distribution Agreement by and between Aziyo Biologics, Inc. and LeMaitre Vascular, Inc. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission F |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 13, 2023 |
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products Exhibit 99.1 Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products SILVER SPRING, Md., July 13, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair prod |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 (June 8, 2023) AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) ( |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 12, 2023 |
Exhibit 10.4 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of May [], 2023, is entered into by and among AZIYO BIOLOGICS, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”) and SWK FUNDING LLC, a Delaware limited liability company, in its capa |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 (May 4, 2023) AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (C |
|
| May 10, 2023 |
Exhibit 99.1 Aziyo Biologics Reports Highest Sales and Gross Profit in Company History - All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need the |
|
| April 27, 2023 |
Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2023 (April 20, 2023) AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporatio |
|
| April 21, 2023 |
Exhibit 99.1 Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio SILVER SPRING, Md., April 20, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced it has entered into a distribution agreem |
|
| April 7, 2023 |
AZYO / Aziyo Biologics Inc - Class A / Birchview Capital, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2312031d1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* AZIYO BIOLOGICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) March 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| March 23, 2023 |
Letter Agreement, dated as of March 22, 2023, by and between Elutia Inc. and Thomas Englese Exhibit 10.15 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 March 22, 2023 Mr. Thomas Englese Re:Termination of Employment Dear Tom: This letter agreement (this “Letter Agreement”) sets forth the understanding by and between you and Aziyo Biologics, Inc. (collectively with its affiliates, and any successor(s) thereto, the “Company”), regarding the termination of y |
|
| March 23, 2023 |
Elutia Inc. 2020 Incentive Award Plan and form of stock option agreements thereunder Exhibit 10.6 AZIYO BIOLOGICS, INC. 2020 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Aziyo Biologics, Inc. 2020 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of Aziyo Biologics, Inc. (the “Company”) by linking the individual interests of Directors, Employees, and Consultants to those of Company st |
|
| March 23, 2023 |
Form of Restricted Stock Unit Award Agreement (approved October 2020) Exhibit 10.8 AZIYO BIOLOGICS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Aziyo Biologics, Inc., a Delaware corporation (the “Company”), pursuant to its 2020 Incentive Award Plan, as amended from time to time (the “Plan”), in connection with its initial public offering, hereby grants to the holder listed below (“Participant”) the numb |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 |
|
| March 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 22, 2023 |
Aziyo Biologics Reports Record Full Year 2022 Revenues Exhibit 99.1 Aziyo Biologics Reports Record Full Year 2022 Revenues SILVER SPRING, Md., March 22, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the fourth quarter and full year ende |
|
| March 21, 2023 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock, $ 0.01 par value (Title of Class of Securities) 05479K106 (CUSIP Number) Endurant Capital Management LP 66 Bovet Road, Suite 353 San Mateo, CA 94402 650-539-5905 (Name, Address and |
|
| March 20, 2023 |
Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope Exhibit 99.1 Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope SILVER SPRING, Md., March 20, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provides an update on its submission to the U.S. Food and Drug Administration (F |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2023 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2023 |
SC 13G/A 1 endurant13g2AZYO12.31.2022.htm ENDURANT13G2AZYO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock, $ 0.01 par value (Title of Class of Securities) 05479K106 (CUSIP Number) Endurant Capital Management LP 66 Bovet Road, Suite 353 San M |
|
| February 14, 2023 |
SC 13G/A 1 endurant13g2AZYO12.31.2022.htm ENDURANT13G2AZYO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock, $ 0.01 par value (Title of Class of Securities) 05479K106 (CUSIP Number) Endurant Capital Management LP 66 Bovet Road, Suite 353 San M |
|
| February 13, 2023 |
AZYO / Aziyo Biologics, Inc. Class A / Birchview Capital, LP - SC 13G/A Passive Investment SC 13G/A 1 tm236390-1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AZIYO BIOLOGICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 9, 2023 |
Exhibit 99.1 Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results SILVER SPRING, Md., January 9, 2023 — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminar |
|
| January 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission F |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2022 |
EX-10.2 3 tm2233784d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), entered into as of December 23, 2022, is made by and between Aziyo Biologics, Inc. (the “Company”) and Thomas Englese (the “Executive”) (collectively referred to herein as the “Parties”). WHEREAS, the Executive is currently employed |
|
| December 30, 2022 |
EX-10.1 2 tm2233784d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), entered into as of December 23, 2022, is made by and between Aziyo Biologics, Inc. (the “Company”) and Matthew Ferguson (the “Executive”) (collectively referred to herein as the “Parties”). WHEREAS, the Executive is currently employe |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| December 15, 2022 |
AZYO / Aziyo Biologics, Inc. Class A / Birchview Capital, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2232730d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AZIYO BIOLOGICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) December 7, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| December 7, 2022 |
Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| December 7, 2022 |
AZYO / Aziyo Biologics, Inc. Class A / HighCape Capital, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) W. Matthew Zuga 36 Church Lane Westport, CT 06880 (646) 793-3510 (Name, Address and Telephone Number of Person Authorized to Receive Notic |
|
| December 5, 2022 |
EX-1.1 2 tm2231343d4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 2,350,000 Shares1 Aziyo Biologics, Inc. Common Stock UNDERWRITING AGREEMENT December 1, 2022 CANTOR FITZGERALD & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Aziyo Biologics, Inc., a Delaware corporation (the “Company”), pro |
|
| December 5, 2022 |
Exhibit 10.1 November 30, 2022 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Email: [email protected] RE: Amendment Letter Ladies and Gentlemen: Reference is made to that certain Credit Agreement, dated as of August 10, 2022, by and among Aziyo Biologics, Inc., a Delaware corporation (the “Borrower”), each of the undersigned financial institutions (individ |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of Incorporation) (Commission |
|
| December 2, 2022 |
2,350,000 Shares Class A Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-267197? PROSPECTUS SUPPLEMENT (To Prospectus dated September 8, 2022) 2,350,000 Shares Class A Common Stock We are offering 2,350,000 shares of our Class A common stock. The purchase price for each share is $4.75. Our Class A common stock is listed on the Nasdaq Capital Market under the symbol ?AZYO.? On November 30, 2022, |
|
| November 30, 2022 |
Subject to Completion, dated November 30, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. |
|
| November 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| November 28, 2022 |
Exhibit 10.1 November 21, 2022 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Email: [email protected] RE:??????????Amendment Letter Ladies and Gentlemen: Reference is made to that certain Credit Agreement, dated as of August 10, 2022, by and among Aziyo Biologics, Inc., a Delaware corporation (the ?Borrower?), each of the undersigned financial institutions (individ |
|
| November 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| November 17, 2022 |
Aziyo Biologics Third Quarter 2022 Financial Results November 14, 2022 Exhibit 99.2 Aziyo Biologics Third Quarter 2022 Financial Results November 14, 2022 Presenters Matt Ferguson - Chief Financial Officer Randal Mills - Co-Founder, President, CEO & Director Kevin Rakin - Executive Chairman Matt Steinberg - FINN Partners Q&A Participants Josh Jennings ? Cowen Simran - Piper Sandler David Rescott ? Truist Securities Operator Good day ladies and gentlemen and thank you |
|
| November 17, 2022 |
Exhibit 99.1 Aziyo Biologics Reports Strong Third Quarter 2022 Revenue Positive meeting with FDA provides clarity for CanGaroo? RM clearance SILVER SPRING, Md., November 14, 2022 (GLOBE NEWSWIRE) ? Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today provided a |
|
| November 14, 2022 |
Form of Restricted Stock Unit Award Agreement (approved August 2022) Exhibit 10.4 ? AZIYO BIOLOGICS, INC. 2020 INCENTIVE AWARD PLAN ? RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT ? Aziyo Biologics, Inc., a Delaware corporation (the ?Company?), pursuant to its 2020 Incentive Award Plan, as amended from time to time (the ?Plan?), in connection with its initial public offering, hereby grants to the holder listed below (?Participant?) th |
|
| November 14, 2022 |
Exhibit 10.3 November 10, 2022 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Email: [email protected] RE:Amendment Letter Ladies and Gentlemen: Reference is made to that certain Credit Agreement, dated as of August 10, 2022, by and among Aziyo Biologics, Inc., a Delaware corporation (the ?Borrower?), each of the undersigned financial institutions (individually each |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| October 24, 2022 |
Exhibit 99.1 Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors Industry veteran brings more than 25 years of healthcare business development and transaction experience SILVER SPRING, Md., October 24, 2022 (GLOBE NEWSWIRE) - Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the a |
|
| October 13, 2022 |
Exhibit 10.1 October 9, 2022 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Email: [email protected] RE: Amendment Letter Ladies and Gentlemen: Reference is made to that certain Credit Agreement, dated as of August 10, 2022, by and among Aziyo Biologics, Inc., a Delaware corporation (the ?Borrower?), each of the undersigned financial institutions (individually each |
|
| October 13, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission F |
|
| September 7, 2022 |
Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 250904 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 250904 September 7, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aziyo Biologics, Inc. Registration Statement on Form S-3 Filed August 31, 2022 File No. 333-267197 To whom it may concern: Pursuant to Rule 461(a) under the Sec |
|
| September 6, 2022 |
United States securities and exchange commission logo September 6, 2022 C. Randal Mills, Ph.D. President and Chief Executive Officer Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 Re: Aziyo Biologics, Inc. Registration Statement on Form S-3 Filed August 31, 2022 File No. 333-267197 Dear Dr. Mills: This is to advise you that we have not reviewed and will not review |
|
| August 31, 2022 |
AZIYO BIOLOGICS, INC. INDEX TO FINANCIAL STATEMENTS Table of Contents Exhibit 99.1 AZIYO BIOLOGICS, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) F-2 ? ? Consolidated Balance Sheets F-3 ? ? Consolidated Statements of Operations F-4 ? ? Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders? Equity (Deficit) F-5 ? ? Consolidated Statements of Cash Flows F-6 ? ? |
|
| August 31, 2022 |
As filed with the Securities and Exchange Commission on August 31, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 31, 2022? Registration No. |
|
| August 31, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Aziyo Biologics, Inc. |
|
| August 31, 2022 |
Financial Statements and Exhibits, Other Events ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2022 ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of incorp |
|
| August 31, 2022 |
Exhibit 4.4 AZIYO BIOLOGICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishm |
|
| August 15, 2022 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT among AZIyo biologics, inc., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of August 10, 2022 [Aziyo] Credit Agreement Table of Contents Page Section 1 Definitions; Interpretation. 1 1.1 Definitions 1 1.2 Interpretation 15 Section 2 Cre |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission F |
|
| August 15, 2022 |
Warrant to Purchase Stock, issued on August 10, 2022, by Aziyo Biologics, Inc.to SWK Funding LLC. Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES OR BLUE SKY LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBST |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission F |
|
| August 11, 2022 |
Exhibit 99.1 Aziyo Biologics Announces Second Quarter 2022 Financial Results and Recent Business Achievements, Including Robust Revenue Growth and Strengthened Balance Sheet SILVER SPRING, Md. ? August 11, 2022 ? Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today provided a business update and reported financial results for the second quarter June 30, 202 |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 21, 2022 |
Exhibit 10.1 Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 20904 June 21, 2022 Mr. Ronald Lloyd [****] [****] Re: Separation and Release of Claims Agreement Dear Ron: This letter agreement ( |
|
| June 21, 2022 |
AZIYO BIOLOGICS APPOINTS DR. C. RANDAL MILLS AS INTERIM PRESIDENT AND CEO Exhibit 99.1 AZIYO BIOLOGICS APPOINTS DR. C. RANDAL MILLS AS INTERIM PRESIDENT AND CEO SILVER SPRING, Md. ? June 21, 2022 ? Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-founder C. Randal (Randy) Mills, Ph.D., ha |
|
| June 21, 2022 |
Exhibit 10.2 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?), entered into as of June 21, 2022 (the ?Effective Date?), is made by and between Aziyo Biologics, Inc. (the ?Company?) and C. Randal Mills (the ?Executive?) (collectively referred to herein as the ?Parties?). WHEREAS, the Company desires to employ the Executive as its Interim President and Chief Execut |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission File |
|
| June 3, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2022 ? ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of incorpora |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 ? ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporat |
|
| May 9, 2022 |
Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results ? SILVER SPRING, Md. |
|
| April 22, 2022 |
DEF 14A 1 tm223659-1def14a.htm DEF 14A TABLE OF CONTENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropri |
|
| April 22, 2022 |
DEFA14A 1 tm223659d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 8, 2022 |
Exhibit 10.3 AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of January 21, 2022, by and among AZIYO BIOLOGICS, INC., a Delaware corporation (?Aziyo?), AZIYO MED, LLC, a Delaware limited liability company (?Aziyo Med?, and Aziyo Med, toget |
|
| March 8, 2022 |
Exhibit 10.4 AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of January 21, 2022, by and among AZIYO BIOLOGICS, INC., a Delaware corporation (?Aziyo?), AZIYO MED, LLC, a Delaware limited liability company (?Aziyo Med?, and Aziyo Med, together with A |
|
| March 8, 2022 |
Subsidiaries of Aziyo Biologics, Inc. Exhibit 21.1 ? SUBSIDIARIES OF AZIYO BIOLOGICS, INC. ? Legal Name of Subsidiary Jurisdiction of Organization Aziyo Med, LLC Delaware ? |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 ? ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of incorpor |
|
| March 3, 2022 |
Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results ? ? Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results ? SILVER SPRING, Md. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock, $ 0.01 par value (Title of Class of Securities) 05479K106 (CUSIP Number) Endurant Capital Management LP 66 Bovet Road, Suite 353 San Mateo, CA 94402 650-539-5905 (Name, Address and Telephone Nu |
|
| February 4, 2022 |
AZIYO BIOLOGICS, INC. 3,301,881 Shares Class A Common Stock Offered by the Selling Securityholders As filed Pursuant to Rule 424(b)(3) Registration No.# 333-262295 PROSPECTUS AZIYO BIOLOGICS, INC. 3,301,881 Shares Class A Common Stock Offered by the Selling Securityholders The selling securityholders may offer and sell up to 3,301,881 shares in the aggregate of Class A common stock identified above, of which 2,122,637 shares are presently issued and outstanding and 1,179,244 shares are issuable |
|
| February 2, 2022 |
Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 250904 Aziyo Biologics, Inc. 12510 Prosperity Drive, Suite 370 Silver Spring, MD 250904 February 2, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aziyo Biologics, Inc. Registration Statement on Form S-3 Filed January 21, 2022 File No. 333-262295 To whom it may concern: Pursuant to Rule 461(a) under the Sec |
|
| January 28, 2022 |
United States securities and exchange commission logo January 28, 2022 Ronald Lloyd President and Chief Executive Officer Aziyo Biologics, Inc. |
|
| January 21, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2022 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of Incorporation) (Commission |
|
| January 21, 2022 |
As filed with the Securities and Exchange Commission on January 21, 2022 S-3 1 tm224036d1s3.htm FORM S-3 As filed with the Securities and Exchange Commission on January 21, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdiction of incorpo |
|
| January 7, 2022 |
Results of Operations and Financial Condition, Other Events ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2021 ? ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of inco |
|
| December 20, 2021 |
AZYO / Aziyo Biologics, Inc. Class A / HIGHCAPE PARTNERS, L.P. - SCHEDULE 13D Activist Investment SC 13D 1 tm2135926d1sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aziyo Biologics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) W. Matthew Zuga 452 5th Avenue, 21st Floor New York, NY 10018 (646) 793-3510 (Name, Address and |
|
| December 20, 2021 |
Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| December 17, 2021 |
AZYO / Aziyo Biologics, Inc. Class A / Birchview Capital, LP - SC 13G Passive Investment SC 13G 1 tm2135683d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AZIYO BIOLOGICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 05479K106 (CUSIP Number) December 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| December 8, 2021 |
Aziyo Biologics Announces $14.0 Million Private Placement Exhibit 99.1 Aziyo Biologics Announces $14.0 Million Private Placement Silver Spring, MD, December 6, 2021 ? Aziyo Biologics, Inc. (the ?Company?) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses. Certain accredited |
|
| December 8, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of December 5, 2021 by and among Aziyo Biologics, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). Recitals A. The Company and each Investor is executing and deliver |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2021 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of Incorporation) (Commission |
|
| December 8, 2021 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of December 5, 2021 by and among Aziyo Biologics, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors identified on Exhibit A attached thereto (t |
|
| November 22, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2021 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2021 |
Aziyo Biologics Reports Third Quarter 2021 Financial Results Aziyo Biologics Reports Third Quarter 2021 Financial Results ? SILVER SPRING, Md. ? November 9, 2021 ? Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2021. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 ? ? AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-39577 47-4790334 (State or other jurisdiction of incor |
|
| October 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2021 AZIYO BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39577 47-4790334 (State or other jurisdiction of incorporation) (Commission |
